MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions
| Active as of 2026-09-15 |
{
"resourceType" : "CodeSystem",
"id" : "mii-cs-onko-weitere-klassifikationen-obds",
"meta" : {
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license",
"valueCode" : "CC-BY-4.0"
},
{
"extension" : [
{
"url" : "packageId",
"valueId" : "de.medizininformatikinitiative.kerndatensatz.onkologie"
},
{
"url" : "version",
"valueString" : "2027.0.0-ballot.1"
},
{
"url" : "uri",
"valueUri" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko"
}
],
"url" : "http://hl7.org/fhir/StructureDefinition/package-source"
}
],
"profile" : [
🔗 "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareablecodesystem"🔗 ,
"http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishablecodesystem"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xml:lang=\"en\" lang=\"en\"><hr/><p><b>English</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem mii-cs-onko-weitere-klassifikationen-obds</b></p><a name=\"mii-cs-onko-weitere-klassifikationen-obds\"> </a><a name=\"hcmii-cs-onko-weitere-klassifikationen-obds\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profiles: <a href=\"http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-shareablecodesystem.html\">CRMI Shareable CodeSystem</a>, <a href=\"http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-publishablecodesystem.html\">CRMI Publishable CodeSystem</a></p></div><p>This case-sensitive code system <code>https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-weitere-klassifikationen-obds</code> defines the following codes in an undefined hierarchy:</p><table class=\"codes\"><tr><td><b>Lvl</b></td><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td>1</td><td style=\"white-space:nowrap\">binet<a name=\"mii-cs-onko-weitere-klassifikationen-obds-binet\"> </a></td><td>BINET Staging System</td><td>Staging system for chronic lymphocytic leukemia based on lymph node involvement and organ enlargement.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0binet-a<a name=\"mii-cs-onko-weitere-klassifikationen-obds-binet-a\"> </a></td><td>BINET A</td><td>Early stage CLL: lymphocytosis in blood and bone marrow only</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0binet-b<a name=\"mii-cs-onko-weitere-klassifikationen-obds-binet-b\"> </a></td><td>BINET B</td><td>Intermediate stage CLL: lymphocytosis with enlarged lymph nodes or spleen/liver</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0binet-c<a name=\"mii-cs-onko-weitere-klassifikationen-obds-binet-c\"> </a></td><td>BINET C</td><td>Advanced stage CLL: lymphocytosis with anemia or thrombocytopenia</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">ann-arbor-stadium<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-stadium\"> </a></td><td>Ann-Arbor Stadium</td><td>Staging system for Hodgkin and Non-Hodgkin lymphomas based on anatomical extent of disease.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-i<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-i\"> </a></td><td>I</td><td>Single lymph node region or single extralymphatic organ</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ia<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ia\"> </a></td><td>IA</td><td>Single lymph node region, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iae<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iae\"> </a></td><td>IAE</td><td>Single lymph node region with extranodal extension, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ib<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ib\"> </a></td><td>IB</td><td>Single lymph node region with B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ibe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ibe\"> </a></td><td>IBE</td><td>Single lymph node region with extranodal extension and B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ie<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ie\"> </a></td><td>IE</td><td>Single extralymphatic organ involvement</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ix<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ix\"> </a></td><td>IX</td><td>Single lymph node region, symptoms unclear</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ixa<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ixa\"> </a></td><td>IXA</td><td>Single lymph node region, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ixae<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ixae\"> </a></td><td>IXAE</td><td>Single lymph node region with extranodal extension, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ixb<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ixb\"> </a></td><td>IXB</td><td>Single lymph node region, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ixbe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ixbe\"> </a></td><td>IXBE</td><td>Single lymph node region with extranodal extension, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ixe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ixe\"> </a></td><td>IXE</td><td>Single extralymphatic organ, symptoms unclear</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii\"> </a></td><td>II</td><td>Two or more lymph node regions on same side of diaphragm</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii1<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii1\"> </a></td><td>II1</td><td>Two lymph node regions on same side of diaphragm</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii1a<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii1a\"> </a></td><td>II1A</td><td>Two lymph node regions on same side of diaphragm, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii1ae<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii1ae\"> </a></td><td>II1AE</td><td>Two lymph node regions on same side of diaphragm with extranodal extension, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii1b<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii1b\"> </a></td><td>II1B</td><td>Two lymph node regions on same side of diaphragm with B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii1be<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii1be\"> </a></td><td>II1BE</td><td>Two lymph node regions on same side of diaphragm with extranodal extension and B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii1e<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii1e\"> </a></td><td>II1E</td><td>Two lymph node regions on same side of diaphragm with extranodal extension</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii1x<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii1x\"> </a></td><td>II1X</td><td>Two lymph node regions on same side of diaphragm, symptoms unclear</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii1xa<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii1xa\"> </a></td><td>II1XA</td><td>Two lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii1xae<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii1xae\"> </a></td><td>II1XAE</td><td>Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii1xb<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii1xb\"> </a></td><td>II1XB</td><td>Two lymph node regions on same side of diaphragm, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii1xbe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii1xbe\"> </a></td><td>II1XBE</td><td>Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii1xe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii1xe\"> </a></td><td>II1XE</td><td>Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii2<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii2\"> </a></td><td>II2</td><td>Multiple lymph node regions on same side of diaphragm</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii2a<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii2a\"> </a></td><td>II2A</td><td>Multiple lymph node regions on same side of diaphragm, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii2ae<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii2ae\"> </a></td><td>II2AE</td><td>Multiple lymph node regions on same side of diaphragm with extranodal extension, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii2b<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii2b\"> </a></td><td>II2B</td><td>Multiple lymph node regions on same side of diaphragm with B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii2be<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii2be\"> </a></td><td>II2BE</td><td>Multiple lymph node regions on same side of diaphragm with extranodal extension and B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii2e<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii2e\"> </a></td><td>II2E</td><td>Multiple lymph node regions on same side of diaphragm with extranodal extension</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii2x<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii2x\"> </a></td><td>II2X</td><td>Multiple lymph node regions on same side of diaphragm, symptoms unclear</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii2xa<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii2xa\"> </a></td><td>II2XA</td><td>Multiple lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii2xae<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii2xae\"> </a></td><td>II2XAE</td><td>Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii2xb<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii2xb\"> </a></td><td>II2XB</td><td>Multiple lymph node regions on same side of diaphragm, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii2xbe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii2xbe\"> </a></td><td>II2XBE</td><td>Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ii2xe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ii2xe\"> </a></td><td>II2XE</td><td>Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iia<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iia\"> </a></td><td>IIA</td><td>Two or more lymph node regions on same side of diaphragm, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiae<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiae\"> </a></td><td>IIAE</td><td>Two or more lymph node regions on same side of diaphragm with extranodal extension, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iib<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iib\"> </a></td><td>IIB</td><td>Two or more lymph node regions on same side of diaphragm with B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iibe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iibe\"> </a></td><td>IIBE</td><td>Two or more lymph node regions on same side of diaphragm with extranodal extension and B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iie<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iie\"> </a></td><td>IIE</td><td>Two or more lymph node regions on same side of diaphragm with extranodal extension</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iix<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iix\"> </a></td><td>IIX</td><td>Two or more lymph node regions on same side of diaphragm, symptoms unclear</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iixa<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iixa\"> </a></td><td>IIXA</td><td>Two or more lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iixae<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iixae\"> </a></td><td>IIXAE</td><td>Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iixb<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iixb\"> </a></td><td>IIXB</td><td>Two or more lymph node regions on same side of diaphragm, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iixbe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iixbe\"> </a></td><td>IIXBE</td><td>Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iixe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iixe\"> </a></td><td>IIXE</td><td>Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iii\"> </a></td><td>III</td><td>Lymph node regions on both sides of diaphragm</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiia<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiia\"> </a></td><td>IIIA</td><td>Lymph node regions on both sides of diaphragm, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiiae<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiiae\"> </a></td><td>IIIAE</td><td>Lymph node regions on both sides of diaphragm with extranodal extension, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiiaes<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiiaes\"> </a></td><td>IIIAES</td><td>Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiias<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiias\"> </a></td><td>IIIAS</td><td>Lymph node regions on both sides of diaphragm with spleen involvement, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiib<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiib\"> </a></td><td>IIIB</td><td>Lymph node regions on both sides of diaphragm with B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiibe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiibe\"> </a></td><td>IIIBE</td><td>Lymph node regions on both sides of diaphragm with extranodal extension and B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiibes<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiibes\"> </a></td><td>IIIBES</td><td>Lymph node regions on both sides of diaphragm with extranodal extension, spleen involvement, and B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiibs<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiibs\"> </a></td><td>IIIBS</td><td>Lymph node regions on both sides of diaphragm with spleen involvement and B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiie<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiie\"> </a></td><td>IIIE</td><td>Lymph node regions on both sides of diaphragm with extranodal extension</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiies<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiies\"> </a></td><td>IIIES</td><td>Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiis<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiis\"> </a></td><td>IIIS</td><td>Lymph node regions on both sides of diaphragm with spleen involvement</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiix<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiix\"> </a></td><td>IIIX</td><td>Lymph node regions on both sides of diaphragm, symptoms unclear</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiixa<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiixa\"> </a></td><td>IIIXA</td><td>Lymph node regions on both sides of diaphragm, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiixae<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiixae\"> </a></td><td>IIIXAE</td><td>Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiixaes<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiixaes\"> </a></td><td>IIIXAES</td><td>Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiixas<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiixas\"> </a></td><td>IIIXAS</td><td>Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiixb<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiixb\"> </a></td><td>IIIXB</td><td>Lymph node regions on both sides of diaphragm, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiixbe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiixbe\"> </a></td><td>IIIXBE</td><td>Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiixbes<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiixbes\"> </a></td><td>IIIXBES</td><td>Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiixbs<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiixbs\"> </a></td><td>IIIXBS</td><td>Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiixe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiixe\"> </a></td><td>IIIXE</td><td>Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiixes<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiixes\"> </a></td><td>IIIXES</td><td>Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iiixs<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iiixs\"> </a></td><td>IIIXS</td><td>Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iii1<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iii1\"> </a></td><td>III1</td><td>Limited lymph node regions on both sides of diaphragm</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iii1a<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iii1a\"> </a></td><td>III1A</td><td>Limited lymph node regions on both sides of diaphragm, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iii1b<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iii1b\"> </a></td><td>III1B</td><td>Limited lymph node regions on both sides of diaphragm with B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iii2<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iii2\"> </a></td><td>III2</td><td>Multiple lymph node regions on both sides of diaphragm</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iii2a<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iii2a\"> </a></td><td>III2A</td><td>Multiple lymph node regions on both sides of diaphragm, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iii2b<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iii2b\"> </a></td><td>III2B</td><td>Multiple lymph node regions on both sides of diaphragm with B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iv<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iv\"> </a></td><td>IV</td><td>Disseminated involvement of one or more extralymphatic organs</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-iva<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-iva\"> </a></td><td>IVA</td><td>Disseminated involvement of extralymphatic organs, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ivae<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ivae\"> </a></td><td>IVAE</td><td>Disseminated involvement of extralymphatic organs with additional extranodal extension, asymptomatic</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ivb<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ivb\"> </a></td><td>IVB</td><td>Disseminated involvement of extralymphatic organs with B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ivbe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ivbe\"> </a></td><td>IVBE</td><td>Disseminated involvement of extralymphatic organs with additional extranodal extension and B symptoms</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ive<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ive\"> </a></td><td>IVE</td><td>Disseminated involvement of extralymphatic organs with extranodal extension</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ivx<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ivx\"> </a></td><td>IVX</td><td>Disseminated involvement of extralymphatic organs, symptoms unclear</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ivxa<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ivxa\"> </a></td><td>IVXA</td><td>Disseminated involvement of extralymphatic organs, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ivxae<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ivxae\"> </a></td><td>IVXAE</td><td>Disseminated involvement of extralymphatic organs with additional extranodal extension, symptoms unclear, asymptomatic features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ivxb<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ivxb\"> </a></td><td>IVXB</td><td>Disseminated involvement of extralymphatic organs, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ivxbe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ivxbe\"> </a></td><td>IVXBE</td><td>Disseminated involvement of extralymphatic organs with additional extranodal extension, symptoms unclear, B symptom features</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ann-arbor-ivxe<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ann-arbor-ivxe\"> </a></td><td>IVXE</td><td>Disseminated involvement of extralymphatic organs with extranodal extension, symptoms unclear</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">iss<a name=\"mii-cs-onko-weitere-klassifikationen-obds-iss\"> </a></td><td>International Staging System</td><td>Staging system for multiple myeloma based on serum beta-2 microglobulin and albumin levels.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0iss-i<a name=\"mii-cs-onko-weitere-klassifikationen-obds-iss-i\"> </a></td><td>ISS I</td><td>Beta-2 microglobulin <3.5 mg/L and albumin ≥3.5 g/dL</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0iss-ii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-iss-ii\"> </a></td><td>ISS II</td><td>Not ISS I or ISS III</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0iss-iii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-iss-iii\"> </a></td><td>ISS III</td><td>Beta-2 microglobulin ≥5.5 mg/L</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">isswm<a name=\"mii-cs-onko-weitere-klassifikationen-obds-isswm\"> </a></td><td>International Scoring System for Waldenström's Macroglobulinemia</td><td>Prognostic scoring system for Waldenström's macroglobulinemia based on age, beta-2 microglobulin, and albumin levels.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0isswm-n<a name=\"mii-cs-onko-weitere-klassifikationen-obds-isswm-n\"> </a></td><td>ISSWM Niedrig</td><td>Low risk: age ≤65 years, beta-2 microglobulin ≤3 mg/L, albumin >3.5 g/dL</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0isswm-i<a name=\"mii-cs-onko-weitere-klassifikationen-obds-isswm-i\"> </a></td><td>ISSWM Intermediär</td><td>Intermediate risk: one adverse factor</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0isswm-h<a name=\"mii-cs-onko-weitere-klassifikationen-obds-isswm-h\"> </a></td><td>ISSWM Hoch</td><td>High risk: age >65 years or beta-2 microglobulin >3 mg/L, or albumin ≤3.5 g/dL (≥2 factors)</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">who-grad<a name=\"mii-cs-onko-weitere-klassifikationen-obds-who-grad\"> </a></td><td>WHO Grade</td><td>World Health Organization grading system for central nervous system tumors based on histological features.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0who-grad-i<a name=\"mii-cs-onko-weitere-klassifikationen-obds-who-grad-i\"> </a></td><td>WHO Grad I</td><td>Well-differentiated, slow-growing, low proliferative potential</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0who-grad-ii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-who-grad-ii\"> </a></td><td>WHO Grad II</td><td>Moderately differentiated, infiltrative, low proliferative potential</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0who-grad-iii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-who-grad-iii\"> </a></td><td>WHO Grad III</td><td>Poorly differentiated, anaplastic, high proliferative potential</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0who-grad-iv<a name=\"mii-cs-onko-weitere-klassifikationen-obds-who-grad-iv\"> </a></td><td>WHO Grad IV</td><td>Poorly differentiated, high mitotic activity, necrosis, microvascular proliferation</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">formen<a name=\"mii-cs-onko-weitere-klassifikationen-obds-formen\"> </a></td><td>Formen</td><td>Classification of lymphoma forms distinguishing classical and variant presentations.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0formen-k<a name=\"mii-cs-onko-weitere-klassifikationen-obds-formen-k\"> </a></td><td>Klassisch</td><td>Classical form of lymphoma presentation</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0formen-v<a name=\"mii-cs-onko-weitere-klassifikationen-obds-formen-v\"> </a></td><td>Variante</td><td>Variant form of lymphoma presentation</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">eln-klassifikation<a name=\"mii-cs-onko-weitere-klassifikationen-obds-eln-klassifikation\"> </a></td><td>ELN-Klassifikation</td><td>European LeukemiaNet risk stratification for acute myeloid leukemia based on cytogenetic and molecular genetic abnormalities.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0eln-g<a name=\"mii-cs-onko-weitere-klassifikationen-obds-eln-g\"> </a></td><td>ELN Günstig</td><td>Favorable risk: good prognosis cytogenetic/molecular markers</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0eln-i1<a name=\"mii-cs-onko-weitere-klassifikationen-obds-eln-i1\"> </a></td><td>ELN Intermediär I</td><td>Intermediate risk I: intermediate prognosis markers</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0eln-i2<a name=\"mii-cs-onko-weitere-klassifikationen-obds-eln-i2\"> </a></td><td>ELN Intermediär II</td><td>Intermediate risk II: intermediate prognosis markers</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0eln-u<a name=\"mii-cs-onko-weitere-klassifikationen-obds-eln-u\"> </a></td><td>ELN Ungünstig</td><td>Unfavorable risk: poor prognosis cytogenetic/molecular markers</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0eln-cp<a name=\"mii-cs-onko-weitere-klassifikationen-obds-eln-cp\"> </a></td><td>ELN Chronische Phase</td><td>Chronic phase (CML context)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0eln-ap<a name=\"mii-cs-onko-weitere-klassifikationen-obds-eln-ap\"> </a></td><td>ELN Akzelierte Phase</td><td>Accelerated phase (CML context)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0eln-bk<a name=\"mii-cs-onko-weitere-klassifikationen-obds-eln-bk\"> </a></td><td>ELN Blastenkrise</td><td>Blast crisis phase (CML context)</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">durie-salmon-stadium<a name=\"mii-cs-onko-weitere-klassifikationen-obds-durie-salmon-stadium\"> </a></td><td>Durie-Salmon Stadium</td><td>Multiple myeloma staging system based on tumor burden and organ function.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0durie-salmon-i<a name=\"mii-cs-onko-weitere-klassifikationen-obds-durie-salmon-i\"> </a></td><td>Durie-Salmon I</td><td>Low tumor burden: hemoglobin >10 g/dL, calcium normal, no bone lesions</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0durie-salmon-ia<a name=\"mii-cs-onko-weitere-klassifikationen-obds-durie-salmon-ia\"> </a></td><td>Durie-Salmon IA</td><td>Low tumor burden with normal renal function</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0durie-salmon-ib<a name=\"mii-cs-onko-weitere-klassifikationen-obds-durie-salmon-ib\"> </a></td><td>Durie-Salmon IB</td><td>Low tumor burden with abnormal renal function</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0durie-salmon-ii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-durie-salmon-ii\"> </a></td><td>Durie-Salmon II</td><td>Intermediate tumor burden: neither stage I nor III criteria</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0durie-salmon-iia<a name=\"mii-cs-onko-weitere-klassifikationen-obds-durie-salmon-iia\"> </a></td><td>Durie-Salmon IIA</td><td>Intermediate tumor burden with normal renal function</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0durie-salmon-iib<a name=\"mii-cs-onko-weitere-klassifikationen-obds-durie-salmon-iib\"> </a></td><td>Durie-Salmon IIB</td><td>Intermediate tumor burden with abnormal renal function</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0durie-salmon-iii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-durie-salmon-iii\"> </a></td><td>Durie-Salmon III</td><td>High tumor burden: hemoglobin <8.5 g/dL, calcium elevated, extensive bone lesions</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0durie-salmon-iiia<a name=\"mii-cs-onko-weitere-klassifikationen-obds-durie-salmon-iiia\"> </a></td><td>Durie-Salmon IIIA</td><td>High tumor burden with normal renal function</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0durie-salmon-iiib<a name=\"mii-cs-onko-weitere-klassifikationen-obds-durie-salmon-iiib\"> </a></td><td>Durie-Salmon IIIB</td><td>High tumor burden with abnormal renal function</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">figo<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo\"> </a></td><td>FIGO</td><td>Staging system of the International Federation of Gynecology and Obstetrics (FIGO) for gynecological malignancies.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-i<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-i\"> </a></td><td>FIGO I</td><td>Tumor confined to the organ of origin</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ia<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ia\"> </a></td><td>FIGO IA</td><td>Stage I with limited local extent (entity-specific definition)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ia1<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ia1\"> </a></td><td>FIGO IA1</td><td>Stage IA, subgroup 1 (e.g. cervix: measured stromal invasion <3 mm)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ia2<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ia2\"> </a></td><td>FIGO IA2</td><td>Stage IA, subgroup 2 (e.g. cervix: measured stromal invasion 3 to <5 mm)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ia3<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ia3\"> </a></td><td>FIGO IA3</td><td>Stage IA, subgroup 3 (entity-specific definition)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ib<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ib\"> </a></td><td>FIGO IB</td><td>Stage I with extended local extent (entity-specific definition)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ib1<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ib1\"> </a></td><td>FIGO IB1</td><td>Stage IB, subgroup 1 (e.g. cervix: invasive carcinoma <2 cm)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ib2<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ib2\"> </a></td><td>FIGO IB2</td><td>Stage IB, subgroup 2 (e.g. cervix: invasive carcinoma 2 to <4 cm)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ib3<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ib3\"> </a></td><td>FIGO IB3</td><td>Stage IB, subgroup 3 (e.g. cervix: invasive carcinoma 4 cm or larger)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ic<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ic\"> </a></td><td>FIGO IC</td><td>Stage I with capsule rupture, surface involvement or malignant ascites</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ic1<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ic1\"> </a></td><td>FIGO IC1</td><td>Stage IC due to intraoperative surgical spill</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ic2<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ic2\"> </a></td><td>FIGO IC2</td><td>Stage IC due to preoperative capsule rupture or surface tumor</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ic3<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ic3\"> </a></td><td>FIGO IC3</td><td>Stage IC due to malignant cells in ascites or peritoneal washings</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ii\"> </a></td><td>FIGO II</td><td>Tumor extending beyond the organ of origin within the pelvis</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iia<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iia\"> </a></td><td>FIGO IIA</td><td>Stage II with limited extension (entity-specific definition)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iia1<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iia1\"> </a></td><td>FIGO IIA1</td><td>Stage IIA, subgroup 1 (e.g. cervix: lesion <4 cm)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iia2<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iia2\"> </a></td><td>FIGO IIA2</td><td>Stage IIA, subgroup 2 (e.g. cervix: lesion 4 cm or larger)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iib<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iib\"> </a></td><td>FIGO IIB</td><td>Stage II with extended extension (entity-specific definition)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iic<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iic\"> </a></td><td>FIGO IIC</td><td>Stage II with capsule rupture, surface involvement or malignant ascites (historical FIGO revisions)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iii\"> </a></td><td>FIGO III</td><td>Tumor with extrapelvic peritoneal spread and/or regional lymph node involvement</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iiia<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iiia\"> </a></td><td>FIGO IIIA</td><td>Stage III with microscopic or limited extrapelvic spread (entity-specific definition)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iiia1<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iiia1\"> </a></td><td>FIGO IIIA1</td><td>Stage III with retroperitoneal lymph node metastasis only</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iiia1i<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iiia1i\"> </a></td><td>FIGO IIIA1(i)</td><td>Stage IIIA1 with lymph node metastasis 10 mm or smaller</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iiia1ii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iiia1ii\"> </a></td><td>FIGO IIIA1(ii)</td><td>Stage IIIA1 with lymph node metastasis larger than 10 mm</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iiia2<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iiia2\"> </a></td><td>FIGO IIIA2</td><td>Stage III with microscopic extrapelvic peritoneal involvement</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iiib<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iiib\"> </a></td><td>FIGO IIIB</td><td>Stage III with macroscopic extrapelvic peritoneal metastasis 2 cm or smaller</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iiic<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iiic\"> </a></td><td>FIGO IIIC</td><td>Stage III with macroscopic extrapelvic peritoneal metastasis larger than 2 cm and/or regional lymph node metastasis</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iiic1<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iiic1\"> </a></td><td>FIGO IIIC1</td><td>Stage III with pelvic lymph node metastasis</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iiic1r<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iiic1r\"> </a></td><td>FIGO IIIC1r</td><td>Stage IIIC1 established by imaging</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iiic1p<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iiic1p\"> </a></td><td>FIGO IIIC1p</td><td>Stage IIIC1 established by pathology</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iiic2<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iiic2\"> </a></td><td>FIGO IIIC2</td><td>Stage III with para-aortic lymph node metastasis</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iiic2r<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iiic2r\"> </a></td><td>FIGO IIIC2r</td><td>Stage IIIC2 established by imaging</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iiic2p<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iiic2p\"> </a></td><td>FIGO IIIC2p</td><td>Stage IIIC2 established by pathology</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iv<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iv\"> </a></td><td>FIGO IV</td><td>Distant metastasis beyond the peritoneal cavity</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-iva<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-iva\"> </a></td><td>FIGO IVA</td><td>Stage IV with spread to adjacent pelvic organs or pleural effusion with positive cytology (entity-specific definition)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ivb<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ivb\"> </a></td><td>FIGO IVB</td><td>Stage IV with distant metastasis including extra-abdominal organs and lymph nodes</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0figo-ivc<a name=\"mii-cs-onko-weitere-klassifikationen-obds-figo-ivc\"> </a></td><td>FIGO IVC</td><td>Stage IV with distant metastasis (entity-specific definition)</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">bismuth<a name=\"mii-cs-onko-weitere-klassifikationen-obds-bismuth\"> </a></td><td>Bismuth</td><td>Classification system for hilar cholangiocarcinoma based on the extent of biliary involvement and resectability.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0bismuth-i<a name=\"mii-cs-onko-weitere-klassifikationen-obds-bismuth-i\"> </a></td><td>Bismuth I</td><td>Tumor below confluence of left and right hepatic ducts</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0bismuth-ii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-bismuth-ii\"> </a></td><td>Bismuth II</td><td>Tumor reaching confluence but not involving secondary ducts</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0bismuth-iii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-bismuth-iii\"> </a></td><td>Bismuth III</td><td>Tumor involving confluence and either right or left secondary ducts</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0bismuth-iiia<a name=\"mii-cs-onko-weitere-klassifikationen-obds-bismuth-iiia\"> </a></td><td>Bismuth IIIA</td><td>Tumor involving confluence and right secondary ducts</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0bismuth-iiib<a name=\"mii-cs-onko-weitere-klassifikationen-obds-bismuth-iiib\"> </a></td><td>Bismuth IIIB</td><td>Tumor involving confluence and left secondary ducts</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0bismuth-iv<a name=\"mii-cs-onko-weitere-klassifikationen-obds-bismuth-iv\"> </a></td><td>Bismuth IV</td><td>Tumor involving confluence and both right and left secondary ducts</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">masaoka<a name=\"mii-cs-onko-weitere-klassifikationen-obds-masaoka\"> </a></td><td>Masaoka</td><td>Staging system for thymomas based on invasiveness and extent of disease.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0masaoka-i<a name=\"mii-cs-onko-weitere-klassifikationen-obds-masaoka-i\"> </a></td><td>Masaoka I</td><td>Encapsulated tumor without invasion</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0masaoka-ii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-masaoka-ii\"> </a></td><td>Masaoka II</td><td>Invasion into surrounding fatty tissue or mediastinal pleura</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0masaoka-iii<a name=\"mii-cs-onko-weitere-klassifikationen-obds-masaoka-iii\"> </a></td><td>Masaoka III</td><td>Invasion into neighboring organs</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0masaoka-iv<a name=\"mii-cs-onko-weitere-klassifikationen-obds-masaoka-iv\"> </a></td><td>Masaoka IV</td><td>Pleural or pericardial dissemination</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0masaoka-iva<a name=\"mii-cs-onko-weitere-klassifikationen-obds-masaoka-iva\"> </a></td><td>Masaoka IVA</td><td>Pleural or pericardial implants</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0masaoka-ivb<a name=\"mii-cs-onko-weitere-klassifikationen-obds-masaoka-ivb\"> </a></td><td>Masaoka IVB</td><td>Lymphogenous or hematogenous metastasis</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">mitoserate-gist<a name=\"mii-cs-onko-weitere-klassifikationen-obds-mitoserate-gist\"> </a></td><td>Mitoserate-GIST</td><td>Mitotic rate assessment for gastrointestinal stromal tumors.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0mitoserate-gist-n<a name=\"mii-cs-onko-weitere-klassifikationen-obds-mitoserate-gist-n\"> </a></td><td>Mitoserate-GIST Niedrig</td><td>Low mitotic rate: ≤5 mitoses per 50 HPF</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0mitoserate-gist-h<a name=\"mii-cs-onko-weitere-klassifikationen-obds-mitoserate-gist-h\"> </a></td><td>Mitoserate-GIST Hoch</td><td>High mitotic rate: >5 mitoses per 50 HPF</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">p16<a name=\"mii-cs-onko-weitere-klassifikationen-obds-p16\"> </a></td><td>p16</td><td>p16 protein expression status assessment.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0p16-p<a name=\"mii-cs-onko-weitere-klassifikationen-obds-p16-p\"> </a></td><td>p16 Positiv</td><td>Positive p16 protein expression</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0p16-n<a name=\"mii-cs-onko-weitere-klassifikationen-obds-p16-n\"> </a></td><td>p16 Negativ</td><td>Negative p16 protein expression</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">eutos-score<a name=\"mii-cs-onko-weitere-klassifikationen-obds-eutos-score\"> </a></td><td>EUTOS-Score</td><td>European Treatment and Outcome Study prognostic score for chronic myeloid leukemia.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0eutos-score-n<a name=\"mii-cs-onko-weitere-klassifikationen-obds-eutos-score-n\"> </a></td><td>EUTOS-Score Niedrigrisiko</td><td>Low risk EUTOS score: ≤87</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0eutos-score-h<a name=\"mii-cs-onko-weitere-klassifikationen-obds-eutos-score-h\"> </a></td><td>EUTOS-Score Hochrisiko</td><td>High risk EUTOS score: >87</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">sanz-score<a name=\"mii-cs-onko-weitere-klassifikationen-obds-sanz-score\"> </a></td><td>Sanz-Score</td><td>Risk assessment score for acute promyelocytic leukemia.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0sanz-score-n<a name=\"mii-cs-onko-weitere-klassifikationen-obds-sanz-score-n\"> </a></td><td>Sanz-Score Niedrig</td><td>Low risk: WBC <10x10⁹/L and platelets >40x10⁹/L</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0sanz-score-i<a name=\"mii-cs-onko-weitere-klassifikationen-obds-sanz-score-i\"> </a></td><td>Sanz-Score Intermediär</td><td>Intermediate risk: WBC <10x10⁹/L and platelets ≤40x10⁹/L</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0sanz-score-h<a name=\"mii-cs-onko-weitere-klassifikationen-obds-sanz-score-h\"> </a></td><td>Sanz-Score Hoch</td><td>High risk: WBC ≥10x10⁹/L</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">ipi<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ipi\"> </a></td><td>IPI</td><td>International Prognostic Index for aggressive non-Hodgkin lymphoma.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ipi-n<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ipi-n\"> </a></td><td>IPI Niedrig</td><td>Low risk: 0-1 risk factors</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ipi-ni<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ipi-ni\"> </a></td><td>IPI Niedrig-Intermediär</td><td>Low-intermediate risk: 2 risk factors</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ipi-hi<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ipi-hi\"> </a></td><td>IPI Hoch-Intermediär</td><td>High-intermediate risk: 3 risk factors</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ipi-h<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ipi-h\"> </a></td><td>IPI Hoch</td><td>High risk: 4-5 risk factors</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">flipi<a name=\"mii-cs-onko-weitere-klassifikationen-obds-flipi\"> </a></td><td>FLIPI</td><td>Follicular Lymphoma International Prognostic Index.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0flipi-l<a name=\"mii-cs-onko-weitere-klassifikationen-obds-flipi-l\"> </a></td><td>FLIPI Low risk</td><td>Low risk: 0-1 risk factors</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0flipi-i<a name=\"mii-cs-onko-weitere-klassifikationen-obds-flipi-i\"> </a></td><td>FLIPI Intermediate risk</td><td>Intermediate risk: 2 risk factors</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0flipi-h<a name=\"mii-cs-onko-weitere-klassifikationen-obds-flipi-h\"> </a></td><td>FLIPI High risk</td><td>High risk: ≥3 risk factors</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">mipi<a name=\"mii-cs-onko-weitere-klassifikationen-obds-mipi\"> </a></td><td>MIPI</td><td>Mantle Cell Lymphoma International Prognostic Index.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0mipi-n<a name=\"mii-cs-onko-weitere-klassifikationen-obds-mipi-n\"> </a></td><td>MIPI Niedrig</td><td>Low risk MIPI score</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0mipi-i<a name=\"mii-cs-onko-weitere-klassifikationen-obds-mipi-i\"> </a></td><td>MIPI Intermediär</td><td>Intermediate risk MIPI score</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0mipi-h<a name=\"mii-cs-onko-weitere-klassifikationen-obds-mipi-h\"> </a></td><td>MIPI Hoch</td><td>High risk MIPI score</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">risikogruppen-ghsg<a name=\"mii-cs-onko-weitere-klassifikationen-obds-risikogruppen-ghsg\"> </a></td><td>Risikogruppen GHSG</td><td>German Hodgkin Study Group risk stratification.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0risikogruppen-ghsg-fr<a name=\"mii-cs-onko-weitere-klassifikationen-obds-risikogruppen-ghsg-fr\"> </a></td><td>GHSG Frühe</td><td>Early favorable risk group</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0risikogruppen-ghsg-i<a name=\"mii-cs-onko-weitere-klassifikationen-obds-risikogruppen-ghsg-i\"> </a></td><td>GHSG Intermediär</td><td>Intermediate risk group</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0risikogruppen-ghsg-fo<a name=\"mii-cs-onko-weitere-klassifikationen-obds-risikogruppen-ghsg-fo\"> </a></td><td>GHSG Fortgeschritten</td><td>Advanced risk group</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">ipss<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ipss\"> </a></td><td>IPSS</td><td>International Prognostic Scoring System for myelodysplastic syndromes.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ipss-l<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ipss-l\"> </a></td><td>IPSS Low</td><td>Low risk: score 0</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ipss-i1<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ipss-i1\"> </a></td><td>IPSS Intermediate-I</td><td>Intermediate-1 risk: score 0.5-1.0</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ipss-i2<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ipss-i2\"> </a></td><td>IPSS Intermediate-II</td><td>Intermediate-2 risk: score 1.5-2.0</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0ipss-h<a name=\"mii-cs-onko-weitere-klassifikationen-obds-ipss-h\"> </a></td><td>IPSS High risk</td><td>High risk: score ≥2.5</td></tr><tr><td>1</td><td style=\"white-space:nowrap\">her2-neu<a name=\"mii-cs-onko-weitere-klassifikationen-obds-her2-neu\"> </a></td><td>HER2-neu</td><td>HER2-neu protein expression and gene amplification status.</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0her2-neu-p<a name=\"mii-cs-onko-weitere-klassifikationen-obds-her2-neu-p\"> </a></td><td>HER2-neu Positiv</td><td>Positive HER2-neu status (IHC 3+ or FISH amplified)</td></tr><tr><td>2</td><td style=\"white-space:nowrap\">\u00a0\u00a0her2-neu-n<a name=\"mii-cs-onko-weitere-klassifikationen-obds-her2-neu-n\"> </a></td><td>HER2-neu Negativ</td><td>Negative HER2-neu status (IHC 0-1+ or FISH not amplified)</td></tr></table></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode" : "shareable"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode" : "publishable"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes",
"code" : "package",
"display" : "Package"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/resource-approvalDate",
"valueDate" : "2026-09-15"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-topic",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C3262"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail" : {
"telecom" : [
{
"system" : "email",
"value" : "thomas.debertshaeuser@charite.de"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-editor",
"valueContactDetail" : {
"name" : "Taskforce Core Data Set"
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail" : {
"name" : "Interoperability Working Group",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail" : {
"name" : "National Steering Committee",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail" : {
"name" : "Interoperability Working Group",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail" : {
"name" : "National Steering Committee",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm",
"valueCoding" : {
"system" : "http://hl7.org/fhir/version-algorithm",
"code" : "semver",
"display" : "SemVer"
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod",
"valuePeriod" : {
"start" : "2027"
}
}
],
"url" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-weitere-klassifikationen-obds",
"version" : "2027.0.0-ballot.1",
"name" : "MII_CS_Onko_Weitere_Klassifikationen_OBDS",
"title" : "MII CodeSystem Onkologie - Weitere Klassifikationen oBDS",
"status" : "active",
"experimental" : false,
"date" : "2026-09-15T06:26:59+00:00",
"publisher" : "Medizininformatik Initiative",
"contact" : [
{
"name" : "Medizininformatik Initiative",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/"
}
]
}
],
"description" : "oBDS-specific classification systems and scoring systems not yet covered by international terminologies (SNOMED CT, NCI Thesaurus). These codes supplement the existing ValueSet for additional classifications. Research required: Check if SNOMED CT or LOINC codes exist for these scoring systems before using oBDS-specific codes.",
"jurisdiction" : [
{
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "DE",
"display" : "Germany"
}
]
}
],
"caseSensitive" : true,
"content" : "complete",
"count" : 219,
"concept" : [
{
"code" : "binet",
"display" : "BINET Staging System",
"definition" : "Staging system for chronic lymphocytic leukemia based on lymph node involvement and organ enlargement.",
"concept" : [
{
"code" : "binet-a",
"display" : "BINET A",
"definition" : "Early stage CLL: lymphocytosis in blood and bone marrow only"
},
{
"code" : "binet-b",
"display" : "BINET B",
"definition" : "Intermediate stage CLL: lymphocytosis with enlarged lymph nodes or spleen/liver"
},
{
"code" : "binet-c",
"display" : "BINET C",
"definition" : "Advanced stage CLL: lymphocytosis with anemia or thrombocytopenia"
}
]
},
{
"code" : "ann-arbor-stadium",
"display" : "Ann-Arbor Stadium",
"definition" : "Staging system for Hodgkin and Non-Hodgkin lymphomas based on anatomical extent of disease.",
"concept" : [
{
"code" : "ann-arbor-i",
"display" : "I",
"definition" : "Single lymph node region or single extralymphatic organ"
},
{
"code" : "ann-arbor-ia",
"display" : "IA",
"definition" : "Single lymph node region, asymptomatic"
},
{
"code" : "ann-arbor-iae",
"display" : "IAE",
"definition" : "Single lymph node region with extranodal extension, asymptomatic"
},
{
"code" : "ann-arbor-ib",
"display" : "IB",
"definition" : "Single lymph node region with B symptoms"
},
{
"code" : "ann-arbor-ibe",
"display" : "IBE",
"definition" : "Single lymph node region with extranodal extension and B symptoms"
},
{
"code" : "ann-arbor-ie",
"display" : "IE",
"definition" : "Single extralymphatic organ involvement"
},
{
"code" : "ann-arbor-ix",
"display" : "IX",
"definition" : "Single lymph node region, symptoms unclear"
},
{
"code" : "ann-arbor-ixa",
"display" : "IXA",
"definition" : "Single lymph node region, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-ixae",
"display" : "IXAE",
"definition" : "Single lymph node region with extranodal extension, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-ixb",
"display" : "IXB",
"definition" : "Single lymph node region, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-ixbe",
"display" : "IXBE",
"definition" : "Single lymph node region with extranodal extension, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-ixe",
"display" : "IXE",
"definition" : "Single extralymphatic organ, symptoms unclear"
},
{
"code" : "ann-arbor-ii",
"display" : "II",
"definition" : "Two or more lymph node regions on same side of diaphragm"
},
{
"code" : "ann-arbor-ii1",
"display" : "II1",
"definition" : "Two lymph node regions on same side of diaphragm"
},
{
"code" : "ann-arbor-ii1a",
"display" : "II1A",
"definition" : "Two lymph node regions on same side of diaphragm, asymptomatic"
},
{
"code" : "ann-arbor-ii1ae",
"display" : "II1AE",
"definition" : "Two lymph node regions on same side of diaphragm with extranodal extension, asymptomatic"
},
{
"code" : "ann-arbor-ii1b",
"display" : "II1B",
"definition" : "Two lymph node regions on same side of diaphragm with B symptoms"
},
{
"code" : "ann-arbor-ii1be",
"display" : "II1BE",
"definition" : "Two lymph node regions on same side of diaphragm with extranodal extension and B symptoms"
},
{
"code" : "ann-arbor-ii1e",
"display" : "II1E",
"definition" : "Two lymph node regions on same side of diaphragm with extranodal extension"
},
{
"code" : "ann-arbor-ii1x",
"display" : "II1X",
"definition" : "Two lymph node regions on same side of diaphragm, symptoms unclear"
},
{
"code" : "ann-arbor-ii1xa",
"display" : "II1XA",
"definition" : "Two lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-ii1xae",
"display" : "II1XAE",
"definition" : "Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-ii1xb",
"display" : "II1XB",
"definition" : "Two lymph node regions on same side of diaphragm, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-ii1xbe",
"display" : "II1XBE",
"definition" : "Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-ii1xe",
"display" : "II1XE",
"definition" : "Two lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear"
},
{
"code" : "ann-arbor-ii2",
"display" : "II2",
"definition" : "Multiple lymph node regions on same side of diaphragm"
},
{
"code" : "ann-arbor-ii2a",
"display" : "II2A",
"definition" : "Multiple lymph node regions on same side of diaphragm, asymptomatic"
},
{
"code" : "ann-arbor-ii2ae",
"display" : "II2AE",
"definition" : "Multiple lymph node regions on same side of diaphragm with extranodal extension, asymptomatic"
},
{
"code" : "ann-arbor-ii2b",
"display" : "II2B",
"definition" : "Multiple lymph node regions on same side of diaphragm with B symptoms"
},
{
"code" : "ann-arbor-ii2be",
"display" : "II2BE",
"definition" : "Multiple lymph node regions on same side of diaphragm with extranodal extension and B symptoms"
},
{
"code" : "ann-arbor-ii2e",
"display" : "II2E",
"definition" : "Multiple lymph node regions on same side of diaphragm with extranodal extension"
},
{
"code" : "ann-arbor-ii2x",
"display" : "II2X",
"definition" : "Multiple lymph node regions on same side of diaphragm, symptoms unclear"
},
{
"code" : "ann-arbor-ii2xa",
"display" : "II2XA",
"definition" : "Multiple lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-ii2xae",
"display" : "II2XAE",
"definition" : "Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-ii2xb",
"display" : "II2XB",
"definition" : "Multiple lymph node regions on same side of diaphragm, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-ii2xbe",
"display" : "II2XBE",
"definition" : "Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-ii2xe",
"display" : "II2XE",
"definition" : "Multiple lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear"
},
{
"code" : "ann-arbor-iia",
"display" : "IIA",
"definition" : "Two or more lymph node regions on same side of diaphragm, asymptomatic"
},
{
"code" : "ann-arbor-iiae",
"display" : "IIAE",
"definition" : "Two or more lymph node regions on same side of diaphragm with extranodal extension, asymptomatic"
},
{
"code" : "ann-arbor-iib",
"display" : "IIB",
"definition" : "Two or more lymph node regions on same side of diaphragm with B symptoms"
},
{
"code" : "ann-arbor-iibe",
"display" : "IIBE",
"definition" : "Two or more lymph node regions on same side of diaphragm with extranodal extension and B symptoms"
},
{
"code" : "ann-arbor-iie",
"display" : "IIE",
"definition" : "Two or more lymph node regions on same side of diaphragm with extranodal extension"
},
{
"code" : "ann-arbor-iix",
"display" : "IIX",
"definition" : "Two or more lymph node regions on same side of diaphragm, symptoms unclear"
},
{
"code" : "ann-arbor-iixa",
"display" : "IIXA",
"definition" : "Two or more lymph node regions on same side of diaphragm, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-iixae",
"display" : "IIXAE",
"definition" : "Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-iixb",
"display" : "IIXB",
"definition" : "Two or more lymph node regions on same side of diaphragm, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-iixbe",
"display" : "IIXBE",
"definition" : "Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-iixe",
"display" : "IIXE",
"definition" : "Two or more lymph node regions on same side of diaphragm with extranodal extension, symptoms unclear"
},
{
"code" : "ann-arbor-iii",
"display" : "III",
"definition" : "Lymph node regions on both sides of diaphragm"
},
{
"code" : "ann-arbor-iiia",
"display" : "IIIA",
"definition" : "Lymph node regions on both sides of diaphragm, asymptomatic"
},
{
"code" : "ann-arbor-iiiae",
"display" : "IIIAE",
"definition" : "Lymph node regions on both sides of diaphragm with extranodal extension, asymptomatic"
},
{
"code" : "ann-arbor-iiiaes",
"display" : "IIIAES",
"definition" : "Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, asymptomatic"
},
{
"code" : "ann-arbor-iiias",
"display" : "IIIAS",
"definition" : "Lymph node regions on both sides of diaphragm with spleen involvement, asymptomatic"
},
{
"code" : "ann-arbor-iiib",
"display" : "IIIB",
"definition" : "Lymph node regions on both sides of diaphragm with B symptoms"
},
{
"code" : "ann-arbor-iiibe",
"display" : "IIIBE",
"definition" : "Lymph node regions on both sides of diaphragm with extranodal extension and B symptoms"
},
{
"code" : "ann-arbor-iiibes",
"display" : "IIIBES",
"definition" : "Lymph node regions on both sides of diaphragm with extranodal extension, spleen involvement, and B symptoms"
},
{
"code" : "ann-arbor-iiibs",
"display" : "IIIBS",
"definition" : "Lymph node regions on both sides of diaphragm with spleen involvement and B symptoms"
},
{
"code" : "ann-arbor-iiie",
"display" : "IIIE",
"definition" : "Lymph node regions on both sides of diaphragm with extranodal extension"
},
{
"code" : "ann-arbor-iiies",
"display" : "IIIES",
"definition" : "Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement"
},
{
"code" : "ann-arbor-iiis",
"display" : "IIIS",
"definition" : "Lymph node regions on both sides of diaphragm with spleen involvement"
},
{
"code" : "ann-arbor-iiix",
"display" : "IIIX",
"definition" : "Lymph node regions on both sides of diaphragm, symptoms unclear"
},
{
"code" : "ann-arbor-iiixa",
"display" : "IIIXA",
"definition" : "Lymph node regions on both sides of diaphragm, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-iiixae",
"display" : "IIIXAE",
"definition" : "Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-iiixaes",
"display" : "IIIXAES",
"definition" : "Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-iiixas",
"display" : "IIIXAS",
"definition" : "Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-iiixb",
"display" : "IIIXB",
"definition" : "Lymph node regions on both sides of diaphragm, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-iiixbe",
"display" : "IIIXBE",
"definition" : "Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-iiixbes",
"display" : "IIIXBES",
"definition" : "Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-iiixbs",
"display" : "IIIXBS",
"definition" : "Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-iiixe",
"display" : "IIIXE",
"definition" : "Lymph node regions on both sides of diaphragm with extranodal extension, symptoms unclear"
},
{
"code" : "ann-arbor-iiixes",
"display" : "IIIXES",
"definition" : "Lymph node regions on both sides of diaphragm with extranodal extension and spleen involvement, symptoms unclear"
},
{
"code" : "ann-arbor-iiixs",
"display" : "IIIXS",
"definition" : "Lymph node regions on both sides of diaphragm with spleen involvement, symptoms unclear"
},
{
"code" : "ann-arbor-iii1",
"display" : "III1",
"definition" : "Limited lymph node regions on both sides of diaphragm"
},
{
"code" : "ann-arbor-iii1a",
"display" : "III1A",
"definition" : "Limited lymph node regions on both sides of diaphragm, asymptomatic"
},
{
"code" : "ann-arbor-iii1b",
"display" : "III1B",
"definition" : "Limited lymph node regions on both sides of diaphragm with B symptoms"
},
{
"code" : "ann-arbor-iii2",
"display" : "III2",
"definition" : "Multiple lymph node regions on both sides of diaphragm"
},
{
"code" : "ann-arbor-iii2a",
"display" : "III2A",
"definition" : "Multiple lymph node regions on both sides of diaphragm, asymptomatic"
},
{
"code" : "ann-arbor-iii2b",
"display" : "III2B",
"definition" : "Multiple lymph node regions on both sides of diaphragm with B symptoms"
},
{
"code" : "ann-arbor-iv",
"display" : "IV",
"definition" : "Disseminated involvement of one or more extralymphatic organs"
},
{
"code" : "ann-arbor-iva",
"display" : "IVA",
"definition" : "Disseminated involvement of extralymphatic organs, asymptomatic"
},
{
"code" : "ann-arbor-ivae",
"display" : "IVAE",
"definition" : "Disseminated involvement of extralymphatic organs with additional extranodal extension, asymptomatic"
},
{
"code" : "ann-arbor-ivb",
"display" : "IVB",
"definition" : "Disseminated involvement of extralymphatic organs with B symptoms"
},
{
"code" : "ann-arbor-ivbe",
"display" : "IVBE",
"definition" : "Disseminated involvement of extralymphatic organs with additional extranodal extension and B symptoms"
},
{
"code" : "ann-arbor-ive",
"display" : "IVE",
"definition" : "Disseminated involvement of extralymphatic organs with extranodal extension"
},
{
"code" : "ann-arbor-ivx",
"display" : "IVX",
"definition" : "Disseminated involvement of extralymphatic organs, symptoms unclear"
},
{
"code" : "ann-arbor-ivxa",
"display" : "IVXA",
"definition" : "Disseminated involvement of extralymphatic organs, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-ivxae",
"display" : "IVXAE",
"definition" : "Disseminated involvement of extralymphatic organs with additional extranodal extension, symptoms unclear, asymptomatic features"
},
{
"code" : "ann-arbor-ivxb",
"display" : "IVXB",
"definition" : "Disseminated involvement of extralymphatic organs, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-ivxbe",
"display" : "IVXBE",
"definition" : "Disseminated involvement of extralymphatic organs with additional extranodal extension, symptoms unclear, B symptom features"
},
{
"code" : "ann-arbor-ivxe",
"display" : "IVXE",
"definition" : "Disseminated involvement of extralymphatic organs with extranodal extension, symptoms unclear"
}
]
},
{
"code" : "iss",
"display" : "International Staging System",
"definition" : "Staging system for multiple myeloma based on serum beta-2 microglobulin and albumin levels.",
"concept" : [
{
"code" : "iss-i",
"display" : "ISS I",
"definition" : "Beta-2 microglobulin <3.5 mg/L and albumin ≥3.5 g/dL"
},
{
"code" : "iss-ii",
"display" : "ISS II",
"definition" : "Not ISS I or ISS III"
},
{
"code" : "iss-iii",
"display" : "ISS III",
"definition" : "Beta-2 microglobulin ≥5.5 mg/L"
}
]
},
{
"code" : "isswm",
"display" : "International Scoring System for Waldenström's Macroglobulinemia",
"definition" : "Prognostic scoring system for Waldenström's macroglobulinemia based on age, beta-2 microglobulin, and albumin levels.",
"concept" : [
{
"code" : "isswm-n",
"display" : "ISSWM Niedrig",
"definition" : "Low risk: age ≤65 years, beta-2 microglobulin ≤3 mg/L, albumin >3.5 g/dL"
},
{
"code" : "isswm-i",
"display" : "ISSWM Intermediär",
"definition" : "Intermediate risk: one adverse factor"
},
{
"code" : "isswm-h",
"display" : "ISSWM Hoch",
"definition" : "High risk: age >65 years or beta-2 microglobulin >3 mg/L, or albumin ≤3.5 g/dL (≥2 factors)"
}
]
},
{
"code" : "who-grad",
"display" : "WHO Grade",
"definition" : "World Health Organization grading system for central nervous system tumors based on histological features.",
"concept" : [
{
"code" : "who-grad-i",
"display" : "WHO Grad I",
"definition" : "Well-differentiated, slow-growing, low proliferative potential"
},
{
"code" : "who-grad-ii",
"display" : "WHO Grad II",
"definition" : "Moderately differentiated, infiltrative, low proliferative potential"
},
{
"code" : "who-grad-iii",
"display" : "WHO Grad III",
"definition" : "Poorly differentiated, anaplastic, high proliferative potential"
},
{
"code" : "who-grad-iv",
"display" : "WHO Grad IV",
"definition" : "Poorly differentiated, high mitotic activity, necrosis, microvascular proliferation"
}
]
},
{
"code" : "formen",
"display" : "Formen",
"definition" : "Classification of lymphoma forms distinguishing classical and variant presentations.",
"concept" : [
{
"code" : "formen-k",
"display" : "Klassisch",
"definition" : "Classical form of lymphoma presentation"
},
{
"code" : "formen-v",
"display" : "Variante",
"definition" : "Variant form of lymphoma presentation"
}
]
},
{
"code" : "eln-klassifikation",
"display" : "ELN-Klassifikation",
"definition" : "European LeukemiaNet risk stratification for acute myeloid leukemia based on cytogenetic and molecular genetic abnormalities.",
"concept" : [
{
"code" : "eln-g",
"display" : "ELN Günstig",
"definition" : "Favorable risk: good prognosis cytogenetic/molecular markers"
},
{
"code" : "eln-i1",
"display" : "ELN Intermediär I",
"definition" : "Intermediate risk I: intermediate prognosis markers"
},
{
"code" : "eln-i2",
"display" : "ELN Intermediär II",
"definition" : "Intermediate risk II: intermediate prognosis markers"
},
{
"code" : "eln-u",
"display" : "ELN Ungünstig",
"definition" : "Unfavorable risk: poor prognosis cytogenetic/molecular markers"
},
{
"code" : "eln-cp",
"display" : "ELN Chronische Phase",
"definition" : "Chronic phase (CML context)"
},
{
"code" : "eln-ap",
"display" : "ELN Akzelierte Phase",
"definition" : "Accelerated phase (CML context)"
},
{
"code" : "eln-bk",
"display" : "ELN Blastenkrise",
"definition" : "Blast crisis phase (CML context)"
}
]
},
{
"code" : "durie-salmon-stadium",
"display" : "Durie-Salmon Stadium",
"definition" : "Multiple myeloma staging system based on tumor burden and organ function.",
"concept" : [
{
"code" : "durie-salmon-i",
"display" : "Durie-Salmon I",
"definition" : "Low tumor burden: hemoglobin >10 g/dL, calcium normal, no bone lesions"
},
{
"code" : "durie-salmon-ia",
"display" : "Durie-Salmon IA",
"definition" : "Low tumor burden with normal renal function"
},
{
"code" : "durie-salmon-ib",
"display" : "Durie-Salmon IB",
"definition" : "Low tumor burden with abnormal renal function"
},
{
"code" : "durie-salmon-ii",
"display" : "Durie-Salmon II",
"definition" : "Intermediate tumor burden: neither stage I nor III criteria"
},
{
"code" : "durie-salmon-iia",
"display" : "Durie-Salmon IIA",
"definition" : "Intermediate tumor burden with normal renal function"
},
{
"code" : "durie-salmon-iib",
"display" : "Durie-Salmon IIB",
"definition" : "Intermediate tumor burden with abnormal renal function"
},
{
"code" : "durie-salmon-iii",
"display" : "Durie-Salmon III",
"definition" : "High tumor burden: hemoglobin <8.5 g/dL, calcium elevated, extensive bone lesions"
},
{
"code" : "durie-salmon-iiia",
"display" : "Durie-Salmon IIIA",
"definition" : "High tumor burden with normal renal function"
},
{
"code" : "durie-salmon-iiib",
"display" : "Durie-Salmon IIIB",
"definition" : "High tumor burden with abnormal renal function"
}
]
},
{
"code" : "figo",
"display" : "FIGO",
"definition" : "Staging system of the International Federation of Gynecology and Obstetrics (FIGO) for gynecological malignancies.",
"concept" : [
{
"code" : "figo-i",
"display" : "FIGO I",
"definition" : "Tumor confined to the organ of origin"
},
{
"code" : "figo-ia",
"display" : "FIGO IA",
"definition" : "Stage I with limited local extent (entity-specific definition)"
},
{
"code" : "figo-ia1",
"display" : "FIGO IA1",
"definition" : "Stage IA, subgroup 1 (e.g. cervix: measured stromal invasion <3 mm)"
},
{
"code" : "figo-ia2",
"display" : "FIGO IA2",
"definition" : "Stage IA, subgroup 2 (e.g. cervix: measured stromal invasion 3 to <5 mm)"
},
{
"code" : "figo-ia3",
"display" : "FIGO IA3",
"definition" : "Stage IA, subgroup 3 (entity-specific definition)"
},
{
"code" : "figo-ib",
"display" : "FIGO IB",
"definition" : "Stage I with extended local extent (entity-specific definition)"
},
{
"code" : "figo-ib1",
"display" : "FIGO IB1",
"definition" : "Stage IB, subgroup 1 (e.g. cervix: invasive carcinoma <2 cm)"
},
{
"code" : "figo-ib2",
"display" : "FIGO IB2",
"definition" : "Stage IB, subgroup 2 (e.g. cervix: invasive carcinoma 2 to <4 cm)"
},
{
"code" : "figo-ib3",
"display" : "FIGO IB3",
"definition" : "Stage IB, subgroup 3 (e.g. cervix: invasive carcinoma 4 cm or larger)"
},
{
"code" : "figo-ic",
"display" : "FIGO IC",
"definition" : "Stage I with capsule rupture, surface involvement or malignant ascites"
},
{
"code" : "figo-ic1",
"display" : "FIGO IC1",
"definition" : "Stage IC due to intraoperative surgical spill"
},
{
"code" : "figo-ic2",
"display" : "FIGO IC2",
"definition" : "Stage IC due to preoperative capsule rupture or surface tumor"
},
{
"code" : "figo-ic3",
"display" : "FIGO IC3",
"definition" : "Stage IC due to malignant cells in ascites or peritoneal washings"
},
{
"code" : "figo-ii",
"display" : "FIGO II",
"definition" : "Tumor extending beyond the organ of origin within the pelvis"
},
{
"code" : "figo-iia",
"display" : "FIGO IIA",
"definition" : "Stage II with limited extension (entity-specific definition)"
},
{
"code" : "figo-iia1",
"display" : "FIGO IIA1",
"definition" : "Stage IIA, subgroup 1 (e.g. cervix: lesion <4 cm)"
},
{
"code" : "figo-iia2",
"display" : "FIGO IIA2",
"definition" : "Stage IIA, subgroup 2 (e.g. cervix: lesion 4 cm or larger)"
},
{
"code" : "figo-iib",
"display" : "FIGO IIB",
"definition" : "Stage II with extended extension (entity-specific definition)"
},
{
"code" : "figo-iic",
"display" : "FIGO IIC",
"definition" : "Stage II with capsule rupture, surface involvement or malignant ascites (historical FIGO revisions)"
},
{
"code" : "figo-iii",
"display" : "FIGO III",
"definition" : "Tumor with extrapelvic peritoneal spread and/or regional lymph node involvement"
},
{
"code" : "figo-iiia",
"display" : "FIGO IIIA",
"definition" : "Stage III with microscopic or limited extrapelvic spread (entity-specific definition)"
},
{
"code" : "figo-iiia1",
"display" : "FIGO IIIA1",
"definition" : "Stage III with retroperitoneal lymph node metastasis only"
},
{
"code" : "figo-iiia1i",
"display" : "FIGO IIIA1(i)",
"definition" : "Stage IIIA1 with lymph node metastasis 10 mm or smaller"
},
{
"code" : "figo-iiia1ii",
"display" : "FIGO IIIA1(ii)",
"definition" : "Stage IIIA1 with lymph node metastasis larger than 10 mm"
},
{
"code" : "figo-iiia2",
"display" : "FIGO IIIA2",
"definition" : "Stage III with microscopic extrapelvic peritoneal involvement"
},
{
"code" : "figo-iiib",
"display" : "FIGO IIIB",
"definition" : "Stage III with macroscopic extrapelvic peritoneal metastasis 2 cm or smaller"
},
{
"code" : "figo-iiic",
"display" : "FIGO IIIC",
"definition" : "Stage III with macroscopic extrapelvic peritoneal metastasis larger than 2 cm and/or regional lymph node metastasis"
},
{
"code" : "figo-iiic1",
"display" : "FIGO IIIC1",
"definition" : "Stage III with pelvic lymph node metastasis"
},
{
"code" : "figo-iiic1r",
"display" : "FIGO IIIC1r",
"definition" : "Stage IIIC1 established by imaging"
},
{
"code" : "figo-iiic1p",
"display" : "FIGO IIIC1p",
"definition" : "Stage IIIC1 established by pathology"
},
{
"code" : "figo-iiic2",
"display" : "FIGO IIIC2",
"definition" : "Stage III with para-aortic lymph node metastasis"
},
{
"code" : "figo-iiic2r",
"display" : "FIGO IIIC2r",
"definition" : "Stage IIIC2 established by imaging"
},
{
"code" : "figo-iiic2p",
"display" : "FIGO IIIC2p",
"definition" : "Stage IIIC2 established by pathology"
},
{
"code" : "figo-iv",
"display" : "FIGO IV",
"definition" : "Distant metastasis beyond the peritoneal cavity"
},
{
"code" : "figo-iva",
"display" : "FIGO IVA",
"definition" : "Stage IV with spread to adjacent pelvic organs or pleural effusion with positive cytology (entity-specific definition)"
},
{
"code" : "figo-ivb",
"display" : "FIGO IVB",
"definition" : "Stage IV with distant metastasis including extra-abdominal organs and lymph nodes"
},
{
"code" : "figo-ivc",
"display" : "FIGO IVC",
"definition" : "Stage IV with distant metastasis (entity-specific definition)"
}
]
},
{
"code" : "bismuth",
"display" : "Bismuth",
"definition" : "Classification system for hilar cholangiocarcinoma based on the extent of biliary involvement and resectability.",
"concept" : [
{
"code" : "bismuth-i",
"display" : "Bismuth I",
"definition" : "Tumor below confluence of left and right hepatic ducts"
},
{
"code" : "bismuth-ii",
"display" : "Bismuth II",
"definition" : "Tumor reaching confluence but not involving secondary ducts"
},
{
"code" : "bismuth-iii",
"display" : "Bismuth III",
"definition" : "Tumor involving confluence and either right or left secondary ducts"
},
{
"code" : "bismuth-iiia",
"display" : "Bismuth IIIA",
"definition" : "Tumor involving confluence and right secondary ducts"
},
{
"code" : "bismuth-iiib",
"display" : "Bismuth IIIB",
"definition" : "Tumor involving confluence and left secondary ducts"
},
{
"code" : "bismuth-iv",
"display" : "Bismuth IV",
"definition" : "Tumor involving confluence and both right and left secondary ducts"
}
]
},
{
"code" : "masaoka",
"display" : "Masaoka",
"definition" : "Staging system for thymomas based on invasiveness and extent of disease.",
"concept" : [
{
"code" : "masaoka-i",
"display" : "Masaoka I",
"definition" : "Encapsulated tumor without invasion"
},
{
"code" : "masaoka-ii",
"display" : "Masaoka II",
"definition" : "Invasion into surrounding fatty tissue or mediastinal pleura"
},
{
"code" : "masaoka-iii",
"display" : "Masaoka III",
"definition" : "Invasion into neighboring organs"
},
{
"code" : "masaoka-iv",
"display" : "Masaoka IV",
"definition" : "Pleural or pericardial dissemination"
},
{
"code" : "masaoka-iva",
"display" : "Masaoka IVA",
"definition" : "Pleural or pericardial implants"
},
{
"code" : "masaoka-ivb",
"display" : "Masaoka IVB",
"definition" : "Lymphogenous or hematogenous metastasis"
}
]
},
{
"code" : "mitoserate-gist",
"display" : "Mitoserate-GIST",
"definition" : "Mitotic rate assessment for gastrointestinal stromal tumors.",
"concept" : [
{
"code" : "mitoserate-gist-n",
"display" : "Mitoserate-GIST Niedrig",
"definition" : "Low mitotic rate: ≤5 mitoses per 50 HPF"
},
{
"code" : "mitoserate-gist-h",
"display" : "Mitoserate-GIST Hoch",
"definition" : "High mitotic rate: >5 mitoses per 50 HPF"
}
]
},
{
"code" : "p16",
"display" : "p16",
"definition" : "p16 protein expression status assessment.",
"concept" : [
{
"code" : "p16-p",
"display" : "p16 Positiv",
"definition" : "Positive p16 protein expression"
},
{
"code" : "p16-n",
"display" : "p16 Negativ",
"definition" : "Negative p16 protein expression"
}
]
},
{
"code" : "eutos-score",
"display" : "EUTOS-Score",
"definition" : "European Treatment and Outcome Study prognostic score for chronic myeloid leukemia.",
"concept" : [
{
"code" : "eutos-score-n",
"display" : "EUTOS-Score Niedrigrisiko",
"definition" : "Low risk EUTOS score: ≤87"
},
{
"code" : "eutos-score-h",
"display" : "EUTOS-Score Hochrisiko",
"definition" : "High risk EUTOS score: >87"
}
]
},
{
"code" : "sanz-score",
"display" : "Sanz-Score",
"definition" : "Risk assessment score for acute promyelocytic leukemia.",
"concept" : [
{
"code" : "sanz-score-n",
"display" : "Sanz-Score Niedrig",
"definition" : "Low risk: WBC <10x10⁹/L and platelets >40x10⁹/L"
},
{
"code" : "sanz-score-i",
"display" : "Sanz-Score Intermediär",
"definition" : "Intermediate risk: WBC <10x10⁹/L and platelets ≤40x10⁹/L"
},
{
"code" : "sanz-score-h",
"display" : "Sanz-Score Hoch",
"definition" : "High risk: WBC ≥10x10⁹/L"
}
]
},
{
"code" : "ipi",
"display" : "IPI",
"definition" : "International Prognostic Index for aggressive non-Hodgkin lymphoma.",
"concept" : [
{
"code" : "ipi-n",
"display" : "IPI Niedrig",
"definition" : "Low risk: 0-1 risk factors"
},
{
"code" : "ipi-ni",
"display" : "IPI Niedrig-Intermediär",
"definition" : "Low-intermediate risk: 2 risk factors"
},
{
"code" : "ipi-hi",
"display" : "IPI Hoch-Intermediär",
"definition" : "High-intermediate risk: 3 risk factors"
},
{
"code" : "ipi-h",
"display" : "IPI Hoch",
"definition" : "High risk: 4-5 risk factors"
}
]
},
{
"code" : "flipi",
"display" : "FLIPI",
"definition" : "Follicular Lymphoma International Prognostic Index.",
"concept" : [
{
"code" : "flipi-l",
"display" : "FLIPI Low risk",
"definition" : "Low risk: 0-1 risk factors"
},
{
"code" : "flipi-i",
"display" : "FLIPI Intermediate risk",
"definition" : "Intermediate risk: 2 risk factors"
},
{
"code" : "flipi-h",
"display" : "FLIPI High risk",
"definition" : "High risk: ≥3 risk factors"
}
]
},
{
"code" : "mipi",
"display" : "MIPI",
"definition" : "Mantle Cell Lymphoma International Prognostic Index.",
"concept" : [
{
"code" : "mipi-n",
"display" : "MIPI Niedrig",
"definition" : "Low risk MIPI score"
},
{
"code" : "mipi-i",
"display" : "MIPI Intermediär",
"definition" : "Intermediate risk MIPI score"
},
{
"code" : "mipi-h",
"display" : "MIPI Hoch",
"definition" : "High risk MIPI score"
}
]
},
{
"code" : "risikogruppen-ghsg",
"display" : "Risikogruppen GHSG",
"definition" : "German Hodgkin Study Group risk stratification.",
"concept" : [
{
"code" : "risikogruppen-ghsg-fr",
"display" : "GHSG Frühe",
"definition" : "Early favorable risk group"
},
{
"code" : "risikogruppen-ghsg-i",
"display" : "GHSG Intermediär",
"definition" : "Intermediate risk group"
},
{
"code" : "risikogruppen-ghsg-fo",
"display" : "GHSG Fortgeschritten",
"definition" : "Advanced risk group"
}
]
},
{
"code" : "ipss",
"display" : "IPSS",
"definition" : "International Prognostic Scoring System for myelodysplastic syndromes.",
"concept" : [
{
"code" : "ipss-l",
"display" : "IPSS Low",
"definition" : "Low risk: score 0"
},
{
"code" : "ipss-i1",
"display" : "IPSS Intermediate-I",
"definition" : "Intermediate-1 risk: score 0.5-1.0"
},
{
"code" : "ipss-i2",
"display" : "IPSS Intermediate-II",
"definition" : "Intermediate-2 risk: score 1.5-2.0"
},
{
"code" : "ipss-h",
"display" : "IPSS High risk",
"definition" : "High risk: score ≥2.5"
}
]
},
{
"code" : "her2-neu",
"display" : "HER2-neu",
"definition" : "HER2-neu protein expression and gene amplification status.",
"concept" : [
{
"code" : "her2-neu-p",
"display" : "HER2-neu Positiv",
"definition" : "Positive HER2-neu status (IHC 3+ or FISH amplified)"
},
{
"code" : "her2-neu-n",
"display" : "HER2-neu Negativ",
"definition" : "Negative HER2-neu status (IHC 0-1+ or FISH not amplified)"
}
]
}
]
}